GLG News Analyses of the following article:

Dexamethasone implant a first for macular edema after retinal vein occlusion

Published at: ophthalmologytimes.modernmedicine.com

Ozurdex (Allergan) Uses Billing Structure That May Prevent Acceptance

November 9, 2009

Ozurdex (Allergan) is now on the market and available for ophthalmologists to treat patients with retinal vascular occlusions (RVO).While the technology and treatment may be sound, there may be significant hurdles to overcome from a billing standpoint.Ozurdex may follow the same fate as Lucentis (Genetech). It must compete with a much cheaper drug which has comparable efficacy.

Request a News Analysis

Subscribe to Updates

By RSS

Work for one of the world's leading organizations? Get started now.

Get Intelligently Connected
with the world's leading experts

GLG's 850+ Clients Include:

More than 70% of the world's leading: mutual funds
15 of the leading 20: global banks
7 of the leading 10: global private equity firms
5 of the leading 10: AmLaw firms
Fortune 500^® Companies: in nearly every industry sector, including pharmaceuticals, insurance, chemicals, energy and computer software

Dexamethasone implant a first for macular edema after retinal vein occlusion

Work for one of the world's leading organizations? Get started now.

Get Intelligently Connectedwith the world's leading experts

GLG's 850+ Clients Include:

Get Intelligently Connected
with the world's leading experts